Breathe Well Live Well
|
PharmaPoint: Asthma – Japan Drug Forecast and Market Analysis to 2023
MarketWatch Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with … |
View full post on asthma – Google News
|
PharmaPoint: Asthma – US Drug Forecast and Market Analysis to 2023
MarketWatch Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with … |
View full post on asthma – Google News
|
PharmaPoint: Asthma – 5EU Drug Forecast and Market Analysis to 2023
MarketWatch Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with … |
View full post on asthma – Google News
Fox News |
Heart, Mini-Stroke Risks From Asthma Drug: FDA
WebMD Sept. 29, 2014 — A safety study done by the maker of the asthma drug omalizumab (Xolair) suggests it poses slightly increased but serious risks for heart attacks and mini-strokes known as TIAs (transient ischemic attacks), the FDA says. Because of … FDA slaps cardiovascular warnings on Roche/Novartis asthma blockbuster Xolair FDA says asthma drug Xolair raises risk of heart, brain problems FDA adds cardiovascular risks to Xolair label for asthma treatment |
View full post on asthma – Google News
|
CardioBreak: Asthma Drug, More on RE-LY
MedPage Today The FDA warned about a slight heart attack and transient ischemic attack risk with the asthma drug omalizumab (Xolair), based on its review of safety studies. The warning will be added to the product label. The RE-LY trialists and drugmaker Boehringer … |
View full post on asthma – Google News
Fox News |
FDA says asthma drug Xolair raises risk of heart, brain problems
Fox News The asthma drug Xolair is associated with a higher risk of heart attack, mini-stroke, chest pain and blood clots in the lungs and veins, among other problems, though the extent of increased risk is unclear, the U.S. Food and Drug Administration said on … |
View full post on asthma – Google News
GlobalPost |
UPDATE 1-FDA says asthma drug Xolair raises risk of heart, brain problems
Reuters Xolair is an injectible drug that was originally approved in 2003 to treat moderate to severe asthma in adults and children aged 12 or over whose condition was not controlled by inhaled steroids. The drug is also approved to treat chronic idiopathic … FDA says asthma drug Xolair raises risk of heart, brain problems FDA warns of increased risks of asthma drug Xolair FDA: Asthma Drug May Increase Risk of CV, Cerebrovascular Events |
View full post on asthma – Google News
GlobalPost |
FDA warns of increased risks of asthma drug Xolair
AAP News (subscription) Patients receiving the asthma medication Xolair (omalizumab) may have a slightly higher risk of serious adverse events affecting the cardiovascular and cerebrovascular systems, according to a review by the Food and Drug Administration (FDA). In … FDA: Asthma Drug May Increase Risk of CV, Cerebrovascular Events |
View full post on asthma – Google News
GlobalPost |
FDA says asthma drug Xolair raises risk of heart, brain problems
Yahoo News WASHINGTON (Reuters) – The asthma drug Xolair is associated with a higher risk of heart attack, mini-stroke, chest pain and blood clots in the lungs and veins, among other problems, though the extent of increased risk is unclear, the U.S. Food and Drug … FDA warns of increased risks of asthma drug Xolair FDA: Asthma Drug May Increase Risk of CV, Cerebrovascular Events |
View full post on asthma – Google News
|
FDA says asthma drug Xolair raises risk of heart, brain problems
Reuters WASHINGTON (Reuters) – The asthma drug Xolair is associated with a higher risk of heart attack, mini-stroke, chest pain and blood clots in the lungs and veins, among other problems, though the extent of increased risk is unclear, the U.S. Food and Drug … FDA: Asthma Drug May Increase Risk of CV, Cerebrovascular Events FDA warns of increased risks of asthma drug Xolair Xolair (omalizumab): Drug Safety Communication – Slightly Elevated Risk of … |
View full post on asthma – Google News